1. Home
  2. PPL vs BIIB Comparison

PPL vs BIIB Comparison

Compare PPL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PPL Corporation

PPL

PPL Corporation

HOLD

Current Price

$38.42

Market Cap

24.8B

Sector

Utilities

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.32

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPL
BIIB
Founded
1920
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8B
27.1B
IPO Year
2007
1996

Fundamental Metrics

Financial Performance
Metric
PPL
BIIB
Price
$38.42
$183.32
Analyst Decision
Buy
Buy
Analyst Count
11
27
Target Price
$39.91
$194.72
AVG Volume (30 Days)
9.9M
827.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.99%
N/A
EPS Growth
32.50
N/A
EPS
1.59
8.79
Revenue
$9,042,000,000.00
$9,890,600,000.00
Revenue This Year
$6.18
N/A
Revenue Next Year
$6.03
N/A
P/E Ratio
$23.96
$21.03
Revenue Growth
6.85
2.22
52 Week Low
$32.50
$110.04
52 Week High
$39.09
$202.41

Technical Indicators

Market Signals
Indicator
PPL
BIIB
Relative Strength Index (RSI) 58.50 46.95
Support Level $36.92 $181.24
Resistance Level $39.09 $186.17
Average True Range (ATR) 0.76 5.30
MACD -0.09 -1.14
Stochastic Oscillator 65.68 16.93

Price Performance

Historical Comparison
PPL
BIIB

About PPL PPL Corporation

PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: